Sernova Engages New York-Based LifeSci Advisors as US Investor Relations Partner

Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

(TheNewswire)



Integrated Advisory and Investor Relations Program to Focus on Elevating Company’s Visibility in US Capital Markets Ahead of Projected Corporate Milestones

 

LONDON, ONTARIO - TheNewswire - September 29, 2021 - Sernova Corp. (TSXV:SVA) (OTC:SEOVF) (FSE/XETRA:PSH), a clinical-stage leader in regenerative medicine and cell therapy therapeutics developing a potential “functional cure” for type 1 diabetes (T1D) and other chronic diseases, announced today it has engaged New York-based LifeSci Advisors LLC, a leading investor relations consultancy firm serving life science companies. LifeSci is an investor relations consultancy that will provide institutional investor communications and capital markets outreach services to help Sernova achieve its capital markets objectives via a broad array of initiatives.  

With a global presence, LifeSci Advisors (www.lifesciadvisors.com) provides comprehensive services designed to increase its clients’ visibility within the investment community and to educate institutional investors about the Company. The LifeSci team has substantial experience in equity capital markets and the life science industry, with long-standing relationships among leading institutional investors and senior corporate professionals that it leverages on behalf of its clients.

“We are delighted to engage LifeSci during this exciting time for Sernova,” said Dr. Philip Toleikis, President and CEO of Sernova. “With multiple potential value-creating milestones on the horizon, it is important for us to clearly communicate our value proposition to investors and the industry as we work toward achieving major inflection points. We believe LifeSci has the right team and approach to help us reach the appropriate institutional audience on a global scale, which has the potential to create substantial shareholder value as we execute against our clinical and business objectives.”

The engagement is subject to TSX Venture Exchange acceptance. Under the terms of the engagement, LifeSci Advisors will be engaged for an initial term of up to 12 months, which may be renewed by the parties. In addition to reimbursement of reasonable out-of-pocket expenses, Sernova will pay LifeSci Advisors a services fee of US$210,000.

ABOUT SERNOVA

Sernova is developing regenerative medicine therapeutic solutions using a medical  device (Cell Pouch™) and immune protected therapeutic cells/tissues (i.e., human donor cells, corrected human cells and stem cell-derived cells) to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent diabetes, blood disorders including hemophilia, and other diseases treated through cellular production of proteins or hormones missing or in short supply within the body. For more information, please visit www.sernova.com.

 

ABOUT SERNOVA’S CELL POUCH SYSTEM

The Cell Pouch, as part of the Cell Pouch System, is a novel, proprietary, scalable, implantable macro- encapsulation device solution designed for the long-term survival and function of therapeutic cells. The device upon implantation is designed to incorporate with tissue, forming highly vascularized tissue chambers for the transplantation and function of therapeutic cells, which then release proteins and hormones as required to treat disease.

The Cell Pouch, along with therapeutic cells, has been shown to provide long-term safety and efficacy in small and large animal models of diabetes and has been proven to provide a biologically compatible environment for insulin-producing cells in humans in a Canadian first-in-human study. Sernova is currently conducting a Phase I/II study at the University of Chicago. Positive initial results have been presented at several international scientific conferences.

 

FOR FURTHER INFORMATION, PLEASE CONTACT:

Investors:

Corey Davis, Ph.D.

LifeScience Advisors, LLC

[email protected]

212-915-2577

 

Corporate:

Investor Relations Sernova Corp.

Tel: (519) 858-5126

[email protected]

www.sernova.com

 

FORWARD-LOOKING INFORMATION

This release contains statements that, to the extent they are not recitations of historical facts, may constitute “forward-looking statements” that involve various risks, uncertainties, and assumptions, including, without limitation, statements regarding the prospects, plans, and objectives of the company. Wherever possible, but not always, words such as "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential for" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur are used to identify forward-looking statements. These statements reflect management’s beliefs with respect to future events and are based on information currently available to management on the date such statements were made. Many factors could cause Sernova’s actual results, performances or achievements to not be as anticipated, estimated or intended or to differ materially from those expressed or implied by the forward-looking statements contained in this news release. Such factors could include, but are not limited to, the company’s ability to secure additional financing and licensing arrangements on reasonable terms, or at all; ability to conduct all required preclinical and clinical studies for the company’s Cell Pouch System and/or related technologies, including the timing and results of those trials; ability to obtain all necessary regulatory approvals, or on a timely basis; ability to in-license additional complementary technologies; ability to execute its business strategy and successfully compete in the market; and the inherent risks associated with the development of biotechnology combination products generally. Many of the factors are beyond our control, including those caused by, related to, or impacted by the novel coronavirus pandemic. Investors should consult the company’s quarterly and annual filings available on www.sedar.com for additional information on risks and uncertainties relating to the forward-looking statements. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

    

Copyright (c) 2021 TheNewswire - All rights reserved.